ArticleFrontiers in immunology2025
Development of a ferroptosis-related signature and identification of NOTCH2 as a novel prognostic biomarker in pancreatic cancer.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A review of autophagy in the pancreas: normal physiology and pathophysiology.Autophagy reports · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ferroptosis, a regulated form of iron-dependent cell death, has shown promise as an anti-tumor mechanism. However, its role in pancreatic cancer remains largely unexplored. This study aimed to identify a ferroptosis-related prognostic signature and key biomarkers. Methods: Transcriptomic profiles and clinical data of pancreatic cancer patients were obtained from the GEO and TCGA databases. A prognostic signature was constructed using LASSO and Cox regression analysis. The role of a key gene, NOTCH2, was investigated through somatic mutation, functional enrichment, immune infiltration, and drug sensitivity analysis. Results: We constructed and validated a ferroptosis-related prognostic signature consisting of NOTCH2, KRT18, and H1-2. Patients in the high-risk group, as defined by this signature, exhibited significantly worse overall survival. A nomogram integrating the risk score and clinical variables demonstrated excellent accuracy in predicting patient prognosis. We identified NOTCH2 as a key biomarker, showing upregulated expression in pancreatic cancer tissues and cell lines, which correlated with poor prognosis and increased infiltration of M2 macrophages. Functionally, knockdown of NOTCH2 Conclusion: Our study establishes a ferroptosis-related signature for prognostic prediction in pancreatic cancer and identifies NOTCH2 as a critical prognostic biomarker. NOTCH2 may promote pancreatic cancer progression by suppressing ferroptosis, highlighting it as a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.